Nektar Therapeutics (NKTR) Other Accumulated Expenses (2010 - 2026)

Nektar Therapeutics' Other Accumulated Expenses history runs 17 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 65.67% year-over-year to $4.1 million in Q1 2026; TTM through Mar 2026 was $4.1 million, a 65.67% decrease from a year earlier, with the FY2025 full-year figure at $2.7 million, down 72.59% from the prior year.
• Other Accumulated Expenses improved to $4.1 million in Q1 2026 per NKTR's latest filing, from $2.7 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $17.0 million in Q1 2022 and bottomed at $2.7 million in Q4 2025.
• The 5-year median for Other Accumulated Expenses is $8.3 million (2024), against an average of $9.2 million.
• Across the five-year window, Other Accumulated Expenses soared 185.8% in 2024 and tumbled 72.59% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $7.0 million in 2022, then sank by 50.44% to $3.5 million in 2023, then surged by 185.8% to $9.9 million in 2024, then tumbled by 72.59% to $2.7 million in 2025, then surged by 49.21% to $4.1 million in 2026.
• Per Business Quant, the three latest NKTR Other Accumulated Expenses figures stand at $4.1 million (Q1 2026), $2.7 million (Q4 2025), and $12.1 million (Q3 2025).